Search Press Releases


Savana and The COPD Foundation Partner to Accelerate Innovative Clinical Research into COPD

July 12, 2021

New partnership set to accelerate innovative AI-powered deep Real World Evidence research into finding the missing millions with Chronic Obstructive Pulmonary Disease (COPD) and address unmet needs.

NY, New York, 12 July 2021. - Savana, world leader in deep Real World Evidence (deep RWE) clinical research, and US not-for-profit organization The COPD Foundation announced today that they are partnering to accelerate innovative clinical research into COPD.

The partnership will unlock the clinical data from de-identified, free text in Electronic Health Records (EHRs) to establish a predictive model to identify patients who may have COPD but have not yet been diagnosed. The research aims to find individuals with "pre-COPD" based on known risk factors, and identify commonly used medications that may be associated with improved outcomes for individuals with COPD or those at risk for developing COPD.

The US COPD challenge

Over 16 million people in the United States have COPD1, and up to 60% of COPD cases go undiagnosed.2 According to the World Health Organization, COPD is the third leading cause of death globally and a significant driver of global healthcare costs.3 COPD and symptomatic pre-COPD continue to be a leading cause of disabling symptoms and suffering.

The COPD Foundation was established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations which will make treatment more effective and affordable. The COPD Foundation does this through scientific research, education, advocacy and awareness with the goal of disease prevention, slowed progression, and ultimately a cure.

Read More

COPD Foundation Journal Receives High Ranking

July 06, 2021

For Immediate Release

Washington, DC - Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivate’s June 30, 2021, Journal Citation Report for 2020.

The highly anticipated 2020 impact factor is one journal quality and importance measure. The impact factor calculates how often articles published in the journal in 2018 and 2019 were cited in other published research articles in 2020.

"We are very pleased with our first impact factor," said Mark Dransfield, MD, Editor in Chief of the JCOPDF. "Our journal is only seven years old, launched in 2014 by founding Editor in Chief James D. Crapo, MD, and the COPD Foundation’s founder, the late John W. Walsh. They envisioned an open access journal that could become the publishing home for important COPD-related research. And now their vision has been validated with this impact factor which categorizes the JCOPDF as the highest-ranked COPD-focused journal."

Devoted to publishing original research, reviews, and perspectives on COPD—the fourth leading cause of death in the United States and the third leading cause of death worldwide—the JCOPDF has an editorial board of global COPD experts from 15 countries. It is published online quarterly with no barriers to access.

Read More

COPD Foundation Welcomes Midmark as Corporate Partner

May 21, 2021

May 21, 2021, Washington, DC — The COPD Foundation is pleased to announce that Midmark, a clinical environmental design company providing medical, dental, and veterinary solutions at the point of care, has recently joined the Foundation’s 2021 Corporate Partners Program.

The COPD Foundation began the corporate partners program in 2015 to interact with external organizations that have the shared goals of undertaking impactful initiatives relating to chronic obstructive pulmonary disease (COPD), bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.

Midmark has decades-long experience in providing spirometry/pulmonary function testing devices to both primary care physicians and specialists but also considers itself an "experience company focused on design" with the goal of reducing steps or burdens to improve the point of care experience for the patient and clinician.

"Understanding the disease, those who live with that disease, and those who care for those with the disease, is essential to understand what is needed AND what is possible to improve the experience at the point of care," explains Thomas D. Schwieterman, MD, MBA, chief medical officer and vice president of clinical affairs at Midmark. "We are designers of complete solutions and we need to fully understand all the stakeholders within COPD care to ensure each stakeholder need is addressed to provide optimal solutions."

Midmark has a broad portfolio of solution-based products which address multiple point of care needs including patient positioning, infection prevention, medical device utilization, clinical workflow, and real-time location monitoring. The company is also active in clinical research with the aim to improve processes and look for next generation techniques and technologies.

Read More

COPD Foundation Supports Proposed Ban on Menthol Cigarettes

April 29, 2021

April 29, 2021, Washington, DC — The COPD Foundation applauds the Biden administration and the U.S. Food and Drug Administration (FDA) on their announcement today to begin the process of banning menthol cigarettes and cigars.

The COPD Foundation joins 80 other national organizations in the Campaign for Tobacco Free Kids coalition in supporting this much-needed action to save lives, reduce youth tobacco addiction and diminish health disparities. Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) along with heart disease, lung cancer, and stroke and is the leading cause of preventable death in the United States.

"This is a historic moment for all of us who work daily to improve the lives of individuals whose health has been critically impacted by the harms of smoking," said Ruth Tal-Singer, President and Chief Scientific Officer of the COPD Foundation. "Menthol is the last remaining 'flavoring' for cigarettes—banning it is a tremendous step towards decreasing the appeal of smoking. Millions of Americans would have been spared the devastating health effects of smoking if menthol cigarettes had never been allowed to exist. Sadly, we cannot rewrite history, but we can support this momentous, bold measure and ensure that more individuals are not ‘recruited’ to smoking by the deceptive, masking properties of menthol and many current smokers are incentivized to quit."

Read More

In Gratitude to Barbara Yawn, MD, MSc Upon Her Retirement from the COPD Foundation

April 28, 2021

Miami, FL April 28, 2021. The COPD Foundation sincerely thanks Barbara Yawn, MD, MSc, for her many years of service to the Foundation, where she has made a lasting impact.

Dr. Yawn has been involved with the Foundation since its inception through her contributions to the Medical and Scientific Advisory Committee (MASAC) and has also worked directly within the Foundation on several key initiatives over the past several years.

As a primary care physician and researcher, Dr. Yawn has provided a unique and critical perspective to the Foundation’s work. During her time with the Foundation, she has championed the inclusion of people with COPD and their caregivers in all aspects of the Foundation’s work and especially in their role as active participants of clinical research teams. Dr. Yawn has grown the COPD Foundation’s Patient-Powered Research Network and served as the principal investigator on several critical studies showcasing the power of the network. In addition, she has advanced the COPD Foundation’s educational efforts including translating research results into understandable language for our patient and caregiver communities.

Read More

Dr. MeiLan Han elected to the COPD Foundation Board of Directors

April 19, 2021

Miami, FL– April 19, 2021 The COPD Foundation, a not-for-profit organization focused on improving the lives of those affected by and stopping the progression of COPD and related lung conditions, has announced the election of Dr. MeiLan Han to its Board of Directors.

"We are delighted to welcome MeiLan to our Board," noted COPD Foundation Board Chair Dr. James D. Crapo. "MeiLan is a longtime researcher and advocate for lung health, and joins a team of supporters that includes noted practitioners who lend their expertise to our mission. We are so appreciative that she will join our team of community leaders committed to improving the lives of patients and caregivers."

MeiLan Han, MD MS, is a Professor of Medicine in the Division of Pulmonary and Critical Care at the University of Michigan. Dr. Han received her medical degree from the University of Washington in Seattle, WA. She completed her residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at the University of Michigan. Dr. Han has also completed a Master's Degree program in Biostatistics and Clinical Study Design at the University of Michigan School of Public Health.

Read More

Pulmonary Rehabilitation - Live Better and Live Longer: a message from 19 Respiratory Organizations

April 07, 2021

Miami, FL April 7, 2021 - Over 16 million people in the United States have COPD1 and up to 60% of COPD cases go undiagnosed.2 According to the World Health Organization, COPD is the third leading cause of death globally.3 COPD continues to be a leading cause of disabling symptoms and suffering. Pulmonary rehabilitation (PR) is the standard of care for persons with COPD and is associated with improved physical function, symptoms, mood and quality of life. Although PR is well established as a highly effective treatment for COPD and other chronic respiratory diseases,4,5 in the United States only 3%–4% of Medicare beneficiaries with COPD receive PR.6 Similarly, low estimates exist for the rest of the world.7

A recent study by Peter Lindenauer and colleagues found that, in persons hospitalized due to acute exacerbation of COPD, PR within 3 months of discharge versus later or no PR, was associated with a highly significant lower risk of mortality at 1 year (hazard ratio, 0.63; i.e., a 37% lower risk of death over the year following discharge).8 The study utilized claims data of 197,376 Medicare beneficiaries discharged after hospitalization for COPD.8 The findings support PR as a high priority following hospitalization for COPD.

Patients suffering from COPD should know that PR not only has potential for helping them feel better and be more independent, but also live longer. We are asking for your support in communicating these important findings of improved survival after PR to providers and patients. Thank you in advance for your help and collaboration.

Read More

COPD Foundation and DevPro Biopharma Join Forces to Develop Treatments for People with COPD and Related Lung Conditions

March 23, 2021

DEVPRO Biopharma | Clinical Research & Development Accelerator
COPD Foundation

Miami, FL, and Basking Ridge, NJ March 23, 2021: The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma LLC, a clinical research and development company, announced that the two organizations have entered into a strategic alliance to develop more effective treatments for people with chronic lung conditions and get them to patients sooner.

The partnership aims to identify potential therapies for COPD and related lung conditions and to accelerate their development and regulatory approval. This alliance leverages DevPro Biopharma’s expertise in the design and implementation of expedient clinical programs and the COPD Foundation’s diverse patient and caregiver community and its network of COPD360Net experts.

"The COPD Foundation is home to many of the world’s leading experts in chronic lung conditions. Now, through their new COPD360Net initiative, they are poised to become leaders in the development of new therapeutics," explained Colin Reisner, MD, DevPro Biopharma's co-founder and CEO. "By joining forces, DevPro Biopharma will direct its expertise to the development of clinical programs to be conducted within the COPD Foundation’s network. We are confident that through this alliance we will have a meaningful impact on patient communities worldwide."

Read More

Holy Cross Health and COPD Foundation Establish Respiratory Navigator and Peer Coach Partnership for People with COPD and Related Lung Conditions

January 21, 2021

FORT LAUDERDALE, FL – Holy Cross Health and the COPD Foundation are pleased to announce the establishment of the Respiratory Navigator and Peer Coach Partnership. Funded by Mr. Herb Yardley, the partnership will launch a pilot program designed for individuals with chronic obstructive pulmonary disease (COPD) and related lung conditions who are hospitalized for exacerbations (flare ups). The program aims to assist patients in the post-acute phase and support their self-management at home.

COPD is a debilitating respiratory condition affecting more than 30 million Americans and 1 million individuals living in Florida. COPD is the 4th leading cause of death in the US and a leading cause of disability. Although COPD is mostly a preventable and manageable chronic condition, low public awareness of the condition and its symptoms often leaves those newly diagnosed unsure how to best manage their care.

Recognizing these challenges, the collaboration between the COPD Foundation and Holy Cross Health has been built to leverage both partners’ resources and strengths. The COPD Foundation focuses on empowering and engaging the COPD community by delivering hope and valuable educational resources to individuals with COPD and their families, so they can take positive steps to lead meaningful and productive lives. The existing Holy Cross Health COPD Navigator program has reduced readmission rates for individuals with COPD by almost 50% by using a dedicated team of health care professional “navigators” who follow each patient through their recovery journey.

Read More

Green Park Collaborative and COPD Foundation Launch coreCOPD to Develop Consensus on Critical Outcomes for Stable Chronic Obstructive Pulmonary Disease

December 23, 2020

Baltimore, MD (December 23, 2020) – The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), is partnering with The COPD Foundation to develop a core set of outcomes to be used in late phase clinical trials of therapies for stable chronic obstructive pulmonary disease (COPD). This initiative, coreCOPD, will engage patients, clinicians, researchers, regulators, payers, health technology assessors, product developers, and other key stakeholders in a structured consensus process to develop the core outcome set.

COPD is a condition characterized by persistent respiratory symptoms and chronic airflow limitation caused by a mixture of small airways disease and parenchymal destruction. Most widely used and accepted clinical outcomes measures in stable COPD clinical trials fail to provide a comprehensive or fully patient-relevant basis for evaluating and comparing the clinical benefit of new therapies. Researchers cannot adequately address this issue, however, because patients and other stakeholders have not yet agreed on which outcomes are most important for their decision making.

"Even in COPD, where many high-quality outcomes are used, multi-stakeholder engagement can yield valuable insights from varied perspectives on deficiencies in customary outcome selections for COPD clinical trials. This work will accelerate the consistent production of more relevant and meaningful data, benefiting healthcare and policy decision-makers and ultimately, the patients they all serve."

Read More

National Health Groups Support COPD Patients at Risk for Severe Effects from COVID-19

November 24, 2020

In honor of World COPD Day, American Lung Association, COPD Foundation offer support for COPD patients and caregivers amid pandemic

CHICAGO (November 18, 2020) – An estimated 16.4 million Americans are living with chronic obstructive pulmonary disease (COPD) – a chronic lung disease that makes it difficult to breathe – which places them at an increased risk for more severe illness from COVID-19. In honor of World COPD Day, and amid the COVID-19 pandemic, the American Lung Association and the COPD Foundation are sharing guidance and highlighting resources and support available to those living with COPD and their caregivers.

"It’s critical that those living with COPD, as well as their caregivers, do all they can to protect their health and reduce their exposure to the virus," said COPD Foundation Chief Medical Officer Byron Thomashow, M.D. "Changes in behavior, such as wearing a face mask, will be key to all of us staying healthy and out of the hospital, especially for those living with COPD, which is already a high-risk disease for readmissions to the hospital."

Questions about COPD management in the COVID era?

The Centers for Disease Control and Prevention (CDC) has identified those living with COPD among those at greater risk for the most severe complications from COVID-19. To protect their health, the American Lung Association and COPD Foundation encourage patients to work with their doctor to help manage their symptoms, stay on their maintenance medications and alert their healthcare provider of any changes in their health or symptoms. The organizations also encourage those living with COPD to reduce their exposure to the virus by utilizing telehealth when available and recommended by their provider, practicing thorough handwashing and avoiding touching their face, wearing a mask, staying physically distant from others and at home, when possible.

Read More

COPD Foundation and American College of Chest Physicians® (CHEST) release report to better understand communication about COPD exacerbations

November 16, 2020

WASHINGTON, DC (November 16, 2020)— To learn more about the experiences of individuals impacted by COPD and the health care professionals supporting them, the COPD Foundation collaborated with the American College of Chest Physicians® (CHEST) to gain valuable information on how those living with or managing COPD perceive exacerbations. Initial results from the survey suggest there are critical gaps in communication between patients with COPD and their health care professionals.

COPD exacerbations adversely impact the health and quality of life of people living with the disease. Frequent exacerbations, and especially those resulting in hospitalizations, lead to greater impairment in daily living, decreased ability to remain in the workplace, and an increased burden on family caregivers. Evidence suggests that those with frequent exacerbations experience worsening lung function, more rapid lung function decline, and are more likely to have longer hospital stays. Readmissions within 30 days of discharge and repeated exacerbations of COPD increase mortality risk in patients with COPD.

"While we as physicians believe we are communicating clearly and well, these data suggest we likely need to explore additional ways to say things in the brief time we have with patients and families. This study provides important insights," said Barbara Yawn, MD, Chief Clinical Officer at the COPD Foundation and Professor of Family Medicine at the University of Minnesota.

Read More

1 2 3 4 5 6 7 8